Carrillo-Esper R, Núñez-Monroy FN

Language: Spanish
References: 42
Page: 127-134
PDF size: 71.30 Kb.

ABSTRACT

Systemic inflammatory response syndrome is secondary to several insults whose purpose is to limit and reverse the injury. The outcome and intensity of the inflammatory response is determined by injury extension and balance between inflammatory and compensatory antiinflammatory responses. The interaction of the several soluble and cellular mediators of inflammatory and antiinflammatory responses determine the next evolutive phases: a) local inflammatory response; b) systemic inflammatory response; c) massive systemic inflammatory response; d) immunologic paralysis; and e) immune dissonance. If the last three phases do not control, cell damage can be amplified and thus perpetuating the infectious process and leading the patient to multiple organ dysfunction. Gamma interferon and steroids as modulators of the inflammatory response, in stages of paralysis and immune dissonance has been studied in clinical and experimental trials with promising results, but more studies to are needed validate their usefulness.

REFERENCES

1. Tilney NL, Bailey GL, Morgan AP. Sequential system failure after rupture of abdominal aortic aneurysms: an unsolved problem in postoperative care. Ann Surg 1973;178:117-22.

2. Baue AE. Multiple, progressive, or sequential systems failure. A syndrome of the 1970's. Arch Surg 1975;110:779-81.

3. Polk HC Jr, Shields CL. Remote organ failure: a valid sign of occult intraabdominal infection. Surgery 1977;81:310-3.

4. Fry DE, Pearlstein L, Fulton RL, Polk HC Jr. Multiple organ failure. The role of uncontrolled infection. Arch Surg 1980;115:136-40.

5. Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120:1109-15.

6. Rangel Frausto MS. The natural history of the systemic response syndrome: a prospective study. JAMA 1995;273: 117- 123.

7. Bone R. Systemic inflammatory response syndrome: a unifyng concept of systemic sepsis and MOF. Alan Fein- Williams & Wilkins. 1997. Ch 1:1:3-11.

8. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure, and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:20: 864-74.

9. Marshal JC, Cook DJ, Christou NC, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638-52.

10. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple- system organ failure and mortality. Chest 1993;103:565-75.

11. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996;24:163-72.

12. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;272: 117-23.

13. Meduri GU, Kohler G, Headley S, et al. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts a poor outcome. Chest 1995;108:1303-14.

14. Casey LC. Roles of cytokines in the pathogenesis of cardiopulmonary induced multisystem organ failure. Ann Thorac Surg 1993;56:S92-S96.

15. Goris RJ. MODS/SIRS: result of an overwhelming inflammatory response? World J Surg 1996;20:418-21.

16. Ogawa M. Systemic inflammatory response syndrome-a concept for avoiding organ dysfunction induced by a "second attack". Surg Today 1998;28:679-81.

17. Baue AE, Durbam R, Faist E. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 1998;10:79- 89.

18. Ziegel EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of Gram-negative bacteremia and shock with human anti- serum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225-30.

19. McCutchan JA, Wolff JL, Ziegler EJ, Braude AI Ineffectiveness of single dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bactereria, Gram-negative infection in patients with prolonged neutropenia Schweiz Med Wochenschr Suppl 1983;165: 695-701.

20. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-35.

21. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995;274:172-77.

22. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin results of a prospective, multicenter, randomized clinical trial. Crit. Care Med 1995;23:994-1006.

23. McCloskey RV, Straube RC, Sanders C, el al. Treatment of septic shock with human monoclonal antibody HA- 1 A: a randomized double- blind, placebo - controlled trial. Ann Intern Med 1994.1212:1-5.

24. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin- 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-44.

25. Abraham E, Wounderink R, Silverman, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor in patients with sepsis syndrome. JAMA 1995;273:934-37.

26. Remik DG. Applied molecular biology of sepsis. J Crit Care1995;10:198-212.

27. Cipolle MD, Pasquale NM, Cerra FB. Secondary organ dysfunction: from clinical perspectives to molecular mediators. Crit Care Clin 1993;9:261- 98.

28. Sigurdsson GH, Christenson JT, Bader el- Rakshy M, et al. Intestinal platelet trapping after traumatic and sepsis shock: an early sign of sepsis and multiorgan failure in critically inpatients? JAMA 1992;20:458-67.

29. Petrak RA, Balk RA. Prostagiandins, cyclo- oxygenase inhibitors, and thromboxane syntehsis inhibitors in the pathogensis of multiple organ failure. Crit Care Clin 1989;35:303-14.

30. Dofferboff AS, Vom VJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute- phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185- 92.

31. Syrbe U, Meineeke A, Platzer C, et al. lmprovement of monocyte function- a new therapeytic approach? In: Sepsis: current prespectives in pathophysiology and therrapy. New York: Springer Verlag; 1994. p. 473-500.

32. Mills CD, Caldwell NM, Gann DJ. Evidence of a plama-mediated "window" of immunodeficiency in rats following trauma. J Clin lmmunol 1989;9:139-50.

33. Platzer C, Meisel C, Vogt K, et al. Up- regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int lmmunol 1995;7:517-23.

34. Kox WJ, Bone RC, Krausch D, et al. Interferon-gama in the treatment of the compensatory anti-inflammatory response syndrome (CARS)-a new approach: proof of principle. Arch Inter Med 1997;21:389-93.

35. Randow F, Syrbe U, Meisel C, et al. Mechanisms of endotoxin desensitization: involvement of interleukin-10 and transformation growth factor beta. J Exp Med 1995;181:1887-92.

36. Livingston DH, Appel SH, Welllhaysen SR, et al. Depressed interferon-gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 1988;123:1309-13.

37. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High levels of interleukin 10 in serum are associated with a fatality in meningococcal disease. Infect lmmun 1995;63:2109-12.

38. Bone RC. Sir lsaac Newton, Sepsis, SIRS and CARS. Crit Care Med 1996;24:1125-1128.

39. Bone RC. lmmunologic dissonance: a continuing evolution in our understanding of systemic inflammatory response syndrome (SIRS) and the multiple organ dysfuction syndrome. Ann Inter Med 1996;125:680-87.

40. Szabo G, Kodys K, Miller-Graziano CL. Elevated monocyte interleukin 6 production in immunosuppressed trauma patients. J Clin lmmunol 1991;11:326-35.

41. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple- system organ failure and mortality. Chest 1993;103:565-75.

42. Brun-Buisson